Perrigo to sell Infant Formula business to MeridianMade for up to $175 million
Perrigo agreed to sell its Infant Formula business to MeridianMade for total consideration of up to $175 million, including $40 million in cash at closing and up to $135 million contingent on performance milestones through 2030. The company expects a non-cash impairment charge of $275 million to $375 million in the fourth quarter of 2026, and says the deal should enhance its margin profile and significantly reduce future capital expenditures.
Key points
- Total consideration of up to $175 million: $40 million cash at closing plus up to $135 million contingent on milestones through 2030
- Expected non-cash impairment charge of $275 million to $375 million in the fourth quarter of 2026
- In the trailing four quarters ended June 27, 2026, Infant Formula generated net sales of $380 million and segment adjusted operating income of $8 million
- Closing is expected in the first half of 2027, subject to customary closing conditions and regulatory approvals
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 7, 2026, 11:17 PM ET, from the text of the filing and its press-release exhibits only.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.